Skip to main content

Alcanza Clinical Research Announces Strategic Acquisition of Tampa Bay Medical Research





Expanding clinical trial capabilities in Florida through the addition of a long-standing, patient-focused research organization

CLEARWATER, FL, January 05, 2026 /24-7PressRelease/ -- Alcanza Clinical Research today announced the acquisition of Tampa Bay Medical Research (TBMR), a respected independent clinical research center with a nearly four-decade legacy of advancing medical science and patient care. Founded in 1984, TBMR has completed more than 600 clinical trials across a broad spectrum of therapeutic areas for more than 70 pharmaceutical and medical device sponsors, bringing cutting-edge therapies closer to patients throughout the Tampa Bay region. With facilities totaling over 5000 sq ft in Clearwater and Largo, TBMR has been a trusted partner for both community participants and global sponsors seeking high-quality clinical data and a patient-centric research environment.

TBMR has earned a reputation for excellence in clinical operations, supported by a multidisciplinary team of Principal Investigators, certified clinical research coordinators and support staff. CEO and Medical Director of TBMR, Sureka Bollepalli, MD, a board-certified endocrinologist, is a long-standing leader within the metabolic research community, and has over 20 years of experience conducting NIH and industry-sponsored trials from study initiation through execution and close-out.

"Partnering with high quality clinical research businesses and operators remains a top priority for us. We are very excited to welcome Dr. Bollepalli and her TBMR team to the Alcanza family." said Carlos Orantes, CEO at Alcanza Clinical Research.

"We are excited to begin this next chapter with Alcanza Clinical Research. This partnership strengthens our ability to support patients, deepen community engagement, and expand access to high-quality clinical research—allowing us to advance care and improve lives together," said Dr. Sureka Bollepalli, CEO and Medical Director at Tampa Bay Medical Research.

The acquisition represents a significant milestone in Alcanza's mission to expand its national footprint while preserving the local expertise and personalized care that TBMR participants and sponsors have come to rely on. By integrating TBMR's operational excellence and community presence with Alcanza's scalable infrastructure and strategic partnerships, the combined organization is poised to accelerate clinical research and broaden access to innovative treatment opportunities for patients.

Alcanza Clinical Research is an integrated network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from under-represented communities. The network includes 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout the Southeast, Northeast, Southwest, Midwest, and Puerto Rico. Alcanza supports studies across all trial phases and major therapeutic areas.

Website: https://alcanzaclinical.com

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  241.78
+8.72 (3.74%)
AAPL  262.75
-4.51 (-1.69%)
AMD  213.38
-7.70 (-3.48%)
BAC  57.31
+0.42 (0.73%)
GOOG  313.72
-3.60 (-1.13%)
META  660.61
+1.82 (0.28%)
MSFT  476.52
+3.67 (0.78%)
NVDA  187.50
-0.62 (-0.33%)
ORCL  193.83
+1.24 (0.64%)
TSLA  430.70
-20.97 (-4.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.